Genomics in Cancer of Unknown Primary: Utility in Modern Clinical Practice

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Cancer of unknown primary (CUP) presents as metastatic disease with an unidentified primary tumor.
• CUP is characterized by a poor prognosis, rapid progression, and limited treatment options, often relying on empirical chemotherapy.

Purpose of the Study:

• To highlight the role of modern genomic advances in identifying the tissue of origin (TOO) for CUP.
• To emphasize the potential of genomic data in guiding molecular targeted therapies and immunotherapies for CUP patients.
• To advocate for the routine integration of genomic analysis in the clinical management of CUP.

Main Methods:

• Utilizing whole genome and whole transcriptome sequencing to analyze vast amounts of data.
• Employing predictive algorithms and artificial intelligence to translate genomic data into actionable clinical insights.
• Leveraging liquid biopsies for repeated genomic analysis, especially when tissue acquisition is challenging.

Main Results:

• Genomic data-driven clinical decision-making has demonstrated improved outcomes in recent trials for CUP patients.
• Genomic profiling enables the identification of the primary tumor's tissue of origin (TOO).
• Genomic insights facilitate the application of personalized molecular targeted therapies and immunotherapies.

Conclusions:

• Genomic advances are transforming the management of CUP by enabling precise diagnosis and targeted treatment strategies.
• Routine genomic analysis at diagnosis and throughout treatment is essential for optimizing care for CUP patients.
• Liquid biopsies offer a promising approach for continuous genomic monitoring in CUP management.